FORMULATION, DEVELOPMENT AND EVALUATION OF COLON TARGETTING MICROSPHERE OF OLSALAZIN
Abstract
Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Microspheres have been of particular interest from the pharmaceutical point of view providing the possibility to achieve sustained and controlled drug release. The aim of present work to formulate and characterize colon targeting microsphere of Olsalazine. The maximum percentage yield and entrapment efficiency was found formulation F3. The optimized formulation among other batches subjected to further studies. The zeta potential of the drug-loaded microspheres was measured on a zeta sizer (Malvern Instruments) by determining the electrophoretic mobility in a micro electrophoresis flow cell. All the samples were measured in water at 25°C in triplicate. Results of zeta potential of optimized formulation F3 microspheres were found to be -35.48 mV respectively. The prepared microspheres were stable, spherical particles and showed favorable release profiles in simulated colonic fluid. However, additional evaluation of these carriers can be performed for their probable to treat colonic diseases, as a future scope.
Key words: Olsalazine, Colon targetting microsphere, Formulation, Evaluation
References
Philip AK, Dabas S, Pathak K. Optimized prodrug approach: a means for achieving enhanced anti-inflammatory potential in experimentally induced colitis. J Drug Target. 2009. 17(3):235-241.
Oluwatoyin AO, John TF. In vitro evaluation of khaya and albizia gums as compression coating for drug targeting to the colon. J Pharm Pharmacol. 2005; 57:63-168.
Akala EO, Elekwachi O, Chase V, Johnson H, Lazarre M, Scott K. Organic redoxinitiated polymerization process for the fabrication of hydrogels for colonspecific drug delivery. Drug Dev Ind Pharm. 2003. 29(4):375-386.
Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003. 6(1):33-66.
Basit A, Bloor J. Prespectives on colonic drug delivery, Business briefing. Pharmtech 2003; 185-190.
Watts P, Illum L. Colonic drug delivery. Drug Dev Ind Pharm 1997; 23:893-913.
Wood E, Wilson CG, Hardy JG. The spreading of foam and solution enemas. Int J Pharm 1985; 25:191-197.
Chein YW. Oral Drug Delivery Systems: In Novel drug delivery systems. Vol.50, Marcel Dekker, Inc., New York. 1992, 139- 177.
Maya Sharma, Choudhury PK, Suresh Kumar Dev. Formulation and In-vitro-invivo evaluation of alginate-chitosan microspheres of Glipizide by ionic gelation method. Asian Journal of Pharmaceutical and Clinical Research. 2017;10(7):385-390.
Priyadarshini M K, Parthiban S, Senthil KumarG P, Tamizh Mani T. Preparation and evaluation of microspheres encapsulating Zidovudine, Int J Res Pharma and Nano Sci,3(5), 2014, 461- 468.
Berthold A, Cremer K, Kreuter J. Influence of crosslinking on the acid stability and physicochemical properties of chitosan microspheres. STP Pharm Sci. 1996; 6:358-364.
Dhanaraju M D, Mani Kumar R, Nithya P, Kishan J V N, Thirumurugan G. Controlled delivery of anti-retroviral drug loaded Chitosan cross linked microspheres, Arch Appl Sci Res, 1(2), 2009, 279-86.
Thejeswini K, Sowmya C, Sunitha J, Surekha R. Formulation development and evaluation of microspheres containing Lopinavir, Int J Innovative Pharm Sci Res, 2(8), 2014, 1638-648.
